VERKARRE , Virginie

Last name: VERKARRE

First name: Virginie

2022 (v1)

Journal article

Metadata-only

Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression

Kammerer-Jacquet, Solene-Florence Gandon, Camille Dugay, Frederic

Aims First described in 2014, renal cell carcinoma (RCC) with TFEB amplification (6p21) is a rare molecular subgroup whose diagnosis is challenging. The prognosis and therapeutic implications remain unclear. Methods We report here the clinical, histological, immunohistochemical, and genetic features of nine novel cases. The pathological and...

Uploaded on: December 3, 2022
May 2022 (v1)

Journal article

Metadata-only

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Vano, Yann-Alexandre Elaidi, Réza Bennamoun, Mostefa

No description

Uploaded on: October 16, 2023
May 2022 (v1)

Journal article

Metadata-only

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Vano, Yann-Alexandre Elaidi, Réza Bennamoun, Mostefa

Background: We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic clear-cell renal cell carcinoma. Efficacy profiles might differ with nivolumab and nivolumab-ipilimumab. We therefore...

Uploaded on: April 20, 2023

VERKARRE , Virginie

Recent uploads